ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Peptides for arthritis?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="testiculus" data-source="post: 269014" data-attributes="member: 17128"><p>Glad you're getting some relief. Here's something else that might help if you can find a way to source it:</p><p></p><p><a href="https://jamanetwork.com/journals/jama/fullarticle/2752470" target="_blank">Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis</a></p><p>Key Points</p><p><strong>Question</strong> Does intra-articular administration of sprifermin structurally modify cartilage, as measured by cartilage thickness on quantitative magnetic resonance imaging, in patients with knee osteoarthritis?</p><p></p><p><strong>Findings</strong> In this dose-finding trial including 549 participants randomized to 30 μg or 100 μg of sprifermin every 6 or 12 months vs placebo, there was a significant increase after 2 years in total femorotibial cartilage thickness for 100 μg of sprifermin every 6 months (0.05 mm) and every 12 months (0.04 mm).</p><p></p><p><strong>Meaning</strong> Compared with placebo, intra-articular administration of 100 μg of sprifermin every 6 or 12 months resulted in improvement in femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; the durability of response also was uncertain.</p><p></p><p><a href="https://www.healio.com/news/rheumatology/20210622/sprifermin-maintains-longterm-cartilage-structural-improvements-in-knee-osteoarthritis" target="_blank">Sprifermin maintains long-term cartilage structural improvements in knee osteoarthritis</a></p><p>According to the researchers, sprifermin demonstrated a significant dose response in total femorotibial joint cartilage thickness (<em>P </em>< .001), as well as a 0.05mm mean difference with the 100-µg dose given every 6 months, compared with placebo (95%CI, 0- 0.1), sustained to year 5. In addition, <a href="https://www.healio.com/news/rheumatology/20210504/tanezumab-comparable-to-nsaids-in-womac-pain-function-across-oa-patient-subgroups" target="_blank">WOMAC pain scores</a> improved approximately 50% from baseline in all groups. No participants who received 100µg every 6 months underwent replacement of the treated knee.</p></blockquote><p></p>
[QUOTE="testiculus, post: 269014, member: 17128"] Glad you're getting some relief. Here's something else that might help if you can find a way to source it: [URL='https://jamanetwork.com/journals/jama/fullarticle/2752470']Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis[/URL] Key Points [B]Question[/B] Does intra-articular administration of sprifermin structurally modify cartilage, as measured by cartilage thickness on quantitative magnetic resonance imaging, in patients with knee osteoarthritis? [B]Findings[/B] In this dose-finding trial including 549 participants randomized to 30 μg or 100 μg of sprifermin every 6 or 12 months vs placebo, there was a significant increase after 2 years in total femorotibial cartilage thickness for 100 μg of sprifermin every 6 months (0.05 mm) and every 12 months (0.04 mm). [B]Meaning[/B] Compared with placebo, intra-articular administration of 100 μg of sprifermin every 6 or 12 months resulted in improvement in femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; the durability of response also was uncertain. [URL='https://www.healio.com/news/rheumatology/20210622/sprifermin-maintains-longterm-cartilage-structural-improvements-in-knee-osteoarthritis']Sprifermin maintains long-term cartilage structural improvements in knee osteoarthritis[/URL] According to the researchers, sprifermin demonstrated a significant dose response in total femorotibial joint cartilage thickness ([I]P [/I]< .001), as well as a 0.05mm mean difference with the 100-µg dose given every 6 months, compared with placebo (95%CI, 0- 0.1), sustained to year 5. In addition, [URL='https://www.healio.com/news/rheumatology/20210504/tanezumab-comparable-to-nsaids-in-womac-pain-function-across-oa-patient-subgroups']WOMAC pain scores[/URL] improved approximately 50% from baseline in all groups. No participants who received 100µg every 6 months underwent replacement of the treated knee. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Peptides for arthritis?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top